PMC:7534795 / 44089-44398 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T329","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"T330","span":{"begin":134,"end":142},"obj":"Disease"}],"attributes":[{"id":"A329","pred":"mondo_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A330","pred":"mondo_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"• Barcitinib for hospitalized COVID-19 patients • Non-randomized clinical trial\n• Any adult patient hospitalized with moderate/severe COVID-19\n• Barcitinib + standard care vs. standard care alone\n• Primary outcome of clinical status after 15 days • Barcitinib 2 mg orally daily for 10 days (NCT04321993, 2020)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T367","span":{"begin":0,"end":79},"obj":"Sentence"},{"id":"T368","span":{"begin":80,"end":142},"obj":"Sentence"},{"id":"T369","span":{"begin":143,"end":195},"obj":"Sentence"},{"id":"T370","span":{"begin":196,"end":309},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Barcitinib for hospitalized COVID-19 patients • Non-randomized clinical trial\n• Any adult patient hospitalized with moderate/severe COVID-19\n• Barcitinib + standard care vs. standard care alone\n• Primary outcome of clinical status after 15 days • Barcitinib 2 mg orally daily for 10 days (NCT04321993, 2020)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1310","span":{"begin":39,"end":47},"obj":"Species"},{"id":"1311","span":{"begin":92,"end":99},"obj":"Species"},{"id":"1349","span":{"begin":30,"end":38},"obj":"Disease"},{"id":"1350","span":{"begin":134,"end":139},"obj":"Disease"}],"attributes":[{"id":"A1310","pred":"tao:has_database_id","subj":"1310","obj":"Tax:9606"},{"id":"A1311","pred":"tao:has_database_id","subj":"1311","obj":"Tax:9606"},{"id":"A1349","pred":"tao:has_database_id","subj":"1349","obj":"MESH:C000657245"},{"id":"A1350","pred":"tao:has_database_id","subj":"1350","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"• Barcitinib for hospitalized COVID-19 patients • Non-randomized clinical trial\n• Any adult patient hospitalized with moderate/severe COVID-19\n• Barcitinib + standard care vs. standard care alone\n• Primary outcome of clinical status after 15 days • Barcitinib 2 mg orally daily for 10 days (NCT04321993, 2020)"}